Cosmos Health Inc. (COSM) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, COSM scores 29 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 4 / 20 (ROIC -35%; FCF yield 0%). This is the weakest economic signal: the company is not currently converting capital into positive returns or free cash flow, per the source.
• Whale 13F Flow: 13 / 20 (institutional accumulation and options positioning). This is the strongest pillar, indicating comparatively more institutional and options-based interest than the other pillars.
• Insider Conviction: 3 / 20 (SEC Form 4 and Congressional PTR cluster flow). The low score signals weak insider-side conviction in the source's measurement.
• Macro Regime Fit: 7 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock is modeled to move in line with the broad market, offering no defensive or low-volatility characteristic.
• Forensic Balance Sheet: 2 / 20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5). This is the most alarming pillar; the Altman Z-Score sits in a range typically associated with distress, and the Piotroski F-Score of 3/9 indicates weak fundamental quality.

For a prospective investor evaluating the stock today, the upside case rests almost entirely on the institutional flow pillar and on the recent revenue catalysts discussed below. The valuation tradeoff is stark: with a market capitalization of $27.9M, a 52-week range of $0.16 - $0.95, and a stock price of 0.28, the price has moved sharply over the period, while the underlying forensic and cash-generation metrics remain weak. Any valuation argument must be weighed against a negative ROIC and zero FCF yield. The 2nd-order implication is that revenue growth alone has not translated into cash returns per the source data, so investors would need to see a path to cash conversion before the rating would plausibly improve.

Per the SEC financials, revenue rose from $53.4M (FY 2023) to $54.4M (FY 2024) to $65.3M (FY 2025), while operating losses and net losses persisted in every reported period. Market data reports a gross margin of 12.1%, an operating margin of -25.6%, and a net margin of -29.3%, with ROIC at -35%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, both per the forensic balance sheet pillar. Debt-to-equity is 0.5 per the same pillar. Reported cash is small at $0.7M in FY 2025, and free cash flow was negative in each reported year.

• Revenue update (GREEN, CATALYST): Headlines from Yahoo Finance and Stock Titan report record preliminary nine-month revenue of $54.3 Million, up 19% year over year, and record Q3 revenue of $17.4 Million, and state that the company reaffirmed a 2026 revenue outlook of over $90 Million.
• Analyst initiation (GREEN, CATALYST): Investing.com reports that Noble Capital initiated coverage with an outperform rating.
• Market and options coverage (YELLOW, MARKET WIRE): Moomoo options-chain coverage, Simply Wall St forecast coverage, and TradingView estimates coverage were flagged as market-wire items without a directional fundamental claim.
• Risk watch: Headline revenue growth has not, per the source data, been accompanied by positive operating income, net income, or free cash flow. The 2026 outlook is a company-reported expectation and is not independently verified in the source.
• Proprietary signals: None are listed in the Butterfly Supply-Chain Graph.

• What are the company's specific products, customers, and revenue drivers behind the reported revenue growth?
• What is the path from negative operating and free cash flow to positive cash generation?
• What are the debt levels and terms, given that debt is N/A in the reported financials while the RQD cites a debt-to-equity of 0.5?
• What is the basis for the 2026 revenue outlook of over $90 Million, and what assumptions underlie it?
• What is the analyst consensus, price target, and holder composition that would contextualize the Noble Capital outperform initiation?